Bolt Biotherapeutics pulls in $54 mln Series B


San Francisco Bay Area-based Bolt Biotherapeutics, a biotechnology company focused on the immune system, has secured $54 million in Series B financing. Pivotal bioVenture Partners led the round with participation from Nan Fung Life Sciences, Novo Holdings and Vivo Capital.

Source: Press Release